Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Wave Life Sciences Declares First Submission of Clinical Trial Application for WVE-006, A Groundbreaking RNA Editing Clinical Candidate
Latest Hotspot
3 min read
Wave Life Sciences Declares First Submission of Clinical Trial Application for WVE-006, A Groundbreaking RNA Editing Clinical Candidate
9 September 2023
Wave Life Sciences Ltd. declared today its initial CTA submission for WVE-006 in cases of alpha-1 antitrypsin deficiency AATD.
Read →
An Overview of Ionis Pharmaceutical’s Drug Pipeline
R&D Pipeline
4 min read
An Overview of Ionis Pharmaceutical’s Drug Pipeline
9 September 2023
Ionis Pharmaceuticals, Inc. is a biopharmaceutical company that was founded in 1989 and is headquartered in California, United States.
Read →
X4 Pharmaceuticals has submitted a New Drug Application to the FDA for Mavorixafor WHIM Syndrome
Latest Hotspot
3 min read
X4 Pharmaceuticals has submitted a New Drug Application to the FDA for Mavorixafor WHIM Syndrome
9 September 2023
X4 Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for the approval of once-daily oral mavorixafor in the treatment of WHIM syndrome.
Read →
Rilonacept Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
4 min read
Rilonacept Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
9 September 2023
This article summarized the latest R&D progress of Rilonacept, the Mechanism of Action for Rilonacept, and the drug target R&D trends for Rilonacept.
Read →
Eli Lilly Initiates Phase III Clinical Trials of GLP-1R Agonist Orforglipron in China for the Treatment of Obesity or Overweight
Latest Hotspot
4 min read
Eli Lilly Initiates Phase III Clinical Trials of GLP-1R Agonist Orforglipron in China for the Treatment of Obesity or Overweight
9 September 2023
On September 6, 2023, Eli Lilly has registered a Phase III clinical trial (Study Code: ATTAIN-2) of the oral small molecule GLP-1R agonist Orforglipron (LY3502970) for the treatment of type 2 diabetes patients with obesity or overweight.
Read →
Comprehensive Understanding of 5-HT Receptor Agonists
Comprehensive Understanding of 5-HT Receptor Agonists
9 September 2023
The 5-HT receptor, also known as the serotonin receptor, plays a crucial role in the human body.
Read →
An Overview of Incyte’s Drug Pipeline | Therapeutic Areas
R&D Pipeline
5 min read
An Overview of Incyte’s Drug Pipeline | Therapeutic Areas
9 September 2023
Incyte Corp. founded in 2002 in Wilmington, Delaware, USA, is a global biopharmaceutical company dedicated to the discovery and development of new drugs.
Read →
RemeGen's Telitacicept new indication application for the treatment of Rheumatoid Arthritis has been accepted by the CDE
Latest Hotspot
3 min read
RemeGen's Telitacicept new indication application for the treatment of Rheumatoid Arthritis has been accepted by the CDE
9 September 2023
On September 7, 2023, the new indication for the injectable drug Telitacicept developed by RemeGen was accepted by the Center for Drug Evaluation (CDE) for the treatment of rheumatoid arthritis (RA).
Read →
Unleashing the Power of Idoxuridine: A Comprehensive Review on R&D Breakthroughs
Drug Insights
4 min read
Unleashing the Power of Idoxuridine: A Comprehensive Review on R&D Breakthroughs
9 September 2023
This article summarized the latest R&D progress of Idoxuridine, the Mechanism of Action for Idoxuridine, and the drug target R&D trends for Idoxuridine.
Read →
Shanghai Yingli Pharmaceutical submits a marketing application for PI3Kδ inhibitor, Linperlisib, for new indication for the treatment of Peripheral T-Cell Lymphoma
Latest Hotspot
4 min read
Shanghai Yingli Pharmaceutical submits a marketing application for PI3Kδ inhibitor, Linperlisib, for new indication for the treatment of Peripheral T-Cell Lymphoma
9 September 2023
On September 6, 2023, Shanghai Yingli Pharmaceutical announced that its PI3Kδ inhibitor, Linperlisib, has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China for a new indication filing.
Read →
Latest Research Progress on Adenosine Antagonists
Latest Research Progress on Adenosine Antagonists
9 September 2023
Adenosine receptors play a crucial role in various physiological processes within the human body.
Read →
An Overview of ImmunoGen’s Drug Pipeline
R&D Pipeline
4 min read
An Overview of ImmunoGen’s Drug Pipeline
9 September 2023
ImmunoGen, Inc. is a biopharmaceutical company that was founded in 1981 and is based in Massachusetts, United States.
Read →